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ABSTRACT
TAp63α is a member of the p53 family, which plays a central role in epithelial 
cancers. Recently, a role has emerged for p53 family members in cancer metabolic 
modulation. 
In order to assess whether TAp63α plays a role in cancer metabolism, we 
exploited p53-null osteosarcoma Tet-On Saos-2 cells, in which the expression of 
TAp63α was dependent on doxycycline supplementation to the medium. Metabolomics 
labeling experiments were performed by incubating the cells in 13C-glucose or 13C15N-
glutamine-labeled culture media, as to monitor metabolic fluxes upon induced 
expression of TAp63α.
Induced expression of TAp63α resulted in cell cycle arrest at the G1 phase. From 
a metabolic standpoint, expression of Tap63α promoted glycolysis and the pentose 
phosphate pathway, which was uncoupled from nucleotide biosynthesis, albeit 
prevented oxidative stress in the form of oxidized glutathione. Double 13C-glucose 
and 13C15N-glutamine metabolic labeling confirmed that induced expression of TAp63α 
corresponded to a decreased flux of pyruvate to the Krebs cycle and decreased 
utilization of glutamine for catabolic purposes in the TCA cycle. Results were not 
conclusive in relation to anabolic utilization of labeled glutamine, since it is unclear 
to what extent the observed minor TAp63α-dependent increases of glutamine-derived 
labeling in palmitate could be tied to increased rates of reductive carboxylation and 
de novo synthesis of fatty acids. Finally, bioinformatics elaborations highlighted a 
link between patient survival rates and the co-expression of p63 and rate limiting 
enzymes of the pentose phosphate pathway, G6PD and PGD.
INTRODUCTION
Decades after Warburg’s pioneering observations 
[1], cancer metabolic reprogramming has come to 
be considered a key driver of tumor progression [2] 
and a so-called “hallmark of cancer” [3-5]. Malignant 
transformation is indeed driven by the sequential 
acquisition of mutations to oncogenes and tumor 
suppressor genes, but this is strictly tied to metabolic 
reprogramming in the light of the increasingly documented 
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influence of oncogenes and tumor suppressor genes on 
cell metabolism [6-10]. In this view, a central role has 
recently emerged for p53 and its family members (p63 
and p73) in the modulation of several metabolic pathways 
[9]. Tp53-family members are supposed to maintain cell 
energy and redox poise in response to external stimuli, 
including genotoxic stresses, in a “save or sacrifice” 
fashion [9]. Activation of p53 might also trigger cell death 
or senescence in response to irreversible damage, such as 
extreme genotoxic damage or the activation of oncogenes 
[9]. 
The gene structure of p53-family tumor proteins 
(TP53, TP63 and TP73) is characterized by three 
conserved domains [11], including the N-terminal 
transactivation domain (TA), the central DNA binding 
domain (DBD), and the C-terminal oligomerization 
domain. Owing to the presence of two distinct promoters, 
TP63 and TP73 may utterly result in two diametrically 
opposing classes of proteins: those containing the 
N-terminal TA domain (TAp63 and TAp73) and those 
lacking it (ΔNp63 and ΔNp73), each one characterized by 
distinct and sometimes opposite biological functions [12]. 
In like fashion to p53, TA-proficient isoforms 
of both p63 and p73 have been implicated in tumor 
suppression and protection from metastasis (especially 
in invasive bladder and prostate cancer) [11]. Moreover, 
p63 expression is absolutely essential for limb formation 
and epidermal morphogenesis (integument and tongue) 
including the formation of adnexa (teeth, hair, mammary 
and prostate glands, and sweat and lacrimal glands), skin 
and most epithelial tissues (e.g., prostate and mammary 
glands), while p63-null animals – surviving only a few 
days post-natally - show severe limb truncations or 
absence of limbs and skin, in addition to craniofacial 
malformations [11]. 
Metabolic effects of Tap63-isoforms have been 
anticipated, in analogy to p53 and Tap73. Indeed, although 
p53 plays a well-established role in the inhibition of 
cancer development, it has also been shown to promote 
cell survival in response to transient or mild stress (such 
as nutrient deprivation [13]) by triggering cell cycle 
arrest and boosting anti-oxidant defenses, as to decrease 
ROS levels and allows the cell to cope with DNA 
damage. For example, Tp53 downstream targets include 
Synthesis of Cytochrome c Oxidase 2 (SCO2), a critical 
regulator of the cytochrome c oxidase complex [14], 
and TP53-induced glycolysis and apoptosis regulator 
(TIGAR) [15]), promoting a build-up of early glycolytic 
intermediates and a shift towards the pentose phosphate 
pathway (PPP). In this view, another key target of Tp53 
is glutaminase 2 (GLS2) [16-18], an enzyme involved in 
glutamine metabolism and, indirectly, in the regulation of 
glutathione homeostasis and glutamine-derived glutamate 
fluxes through the Krebs cycle. More recent findings have 
identified carnitine palmitoyltransferase 1C (CPT1C) 
as a novel target of p53 [19]. CPT1C is a brain-specific 
member of a family of mitochondria-associated enzymes 
that play a central role in fatty acid metabolism. CPT1C 
anti-correlates with mammalian target of rapamycin 
(mTOR) pathway activation, and promotes cell survival 
and tumor growth [20]. In fact, CPT1C expression is 
triggered by metabolic stress factors, such as hypoxia and 
glucose deprivation, in a p53 and AMP activated kinase-
dependent manner [20]. Finally, in addition to its nuclear 
localization, the p53 protein has been also detected on the 
mitochondria, and here it seems to be able to affect cell 
respiration as well as interacting with the mitochondrial 
F1F0-ATP synthase[21].
TAp73 has been implicated in autophagy, the control 
of reactive oxygen species (ROS), and the maintenance of 
mitochondrial complex IV [22], other than the induction 
of endoplasmic reticulum (ER) stress, activation of the 
pentose phosphate pathway (PPP) [23] and alteration of 
serine biosynthesis [24]. 
On the other hand, Tap63 might have unique effect 
on cancer cell metabolism. For example, proteomics and 
targeted metabolomics have suggested a peculiar role of 
TAp63 isoforms in enhancing glycolysis [25]. In addition, 
p63 influences lipid metabolism, by increasing fatty acid 
synthesis and decreasing fatty acid oxidation [26].
In 2006, Gressner and colleagues generated a Tet-
On-inducible osteosarcoma (Saos-2) cell line, expressing 
TAp63α in response to doxycycline supplementation to 
the medium. This cell model lends itself to investigate 
the biological role of TAp63α, since Saos-2 cells are 
p53 negative and show no detectable p63 and p73 at 
either mRNA or protein level [27]. The expression of 
TAp63α protein resulted in the induction of p21, and was 
accompanied by cell cycle arrest at the G1 phase and the 
onset of apoptosis [27]. Apoptosis was mediated by the 
TAp63α-triggered expression of the CD95, TNF-R and 
TRAIL-R death receptors [27]. Furthermore, TAp63α 
induced apoptosis via the mitochondrial pathway, 
through the up-regulation of caspases and pro-apoptotic 
Bcl-2 family members, like Bax and BCL2L11, and the 
expression of RAD9, DAP3 and APAF1 [27]. In order 
to gain further insights on TAp63-dependent metabolic 
modulation, in the present study Tet-On TAp63α Saos-
2 cells were cultured in the presence of media either 
containing 13C-glucose or 13C 15N-glutamine stable 
isotopes. While heavy glucose is the most common 
metabolic tracer, in the light of the generality of the 
Warburg effect, the advantages of monitoring cancer cell 
utilization of glutamine are related to the emerging role of 
glutamine metabolism in cancer cells [28,29]. This is in 
keeping with our recent evidence that, in analogy to p53 
and p73 [16,17,24], p63 can modulate the expression of 
GLS2 [30]. 
Our data indicate that TAp63α causes a large series 
of metabolic modulations, involving central carbon 
metabolism (glycolysis, pentose phosphate pathway, 
nucleotide biosynthesis). The present results also suggest 
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that serine and fatty acid catabolism/biosynthesis might 
be affected by Tap63α. In induced cells, catabolism of 
glutamine-derived glutamate through the TCA cycle was 
slower in comparison to non-induced controls. These data 
are relevant to further understand the role of p63 in cancer.
RESULTS AND DISCUSSION
TAp63α promotes glycolysis and PPP pathway, 
uncoupled from nucleotide biosynthesis 
To investigate the metabolic function of TAp63, we 
employed a Tet-On inducible SaOs-2 osteosarcoma cell 
line, carrying the inducible expression vector coding for 
a HA-tagged TAp63α. TAp63α induction was functional 
as it promoted the expression of the direct transcriptional 
target p21 (Suppl. Fig. 1A) resulting in a G1 cycle arrest 
(Suppl. Fig. 1B), consistently with the literature[27]. 
To assess whether TAp63 has any regulatory effects 
on the glucose flux, we induced Tap63α expression by 
supplementing doxycycline to the medium. After 24h we 
replaced cell media with DMEM containing 13C-glucose 
stable isotopes. MS analysis revealed that glucose 
consumption via glycolysis was increased in TAp63α 
expressing cells compared to untreated controls. In 
particular, intracellular labeled glucose was significantly 
higher in doxycycline-supplemented units (Fig. 1B). In 
addition induced expression of TAp63α corresponded to 
a statistically significant accumulation of early (M+6) 
and late (M+3) glycolytic intermediates (Fig. 1B). This 
increase of glycolytic rate also corresponded to a faster 
rate of intracellular lactate accumulation (Fig. 1B). These 
results are consistent with recent proteomics and targeted 
metabolomics evidence about a role of TAp63 isoforms in 
enhancing glycolysis in colon cancer stem cells[25].
Increased glycolysis might be also associated 
Figure 1: Effect on glycolysis. (A). A simplified overview of glycolysis, pentose phosphate pathway and hexosamine pathway. 
Abbreviated metabolites and enzymes (Uniprot names) are reported in black and gray, respectively. (B) Isotopomer distribution of 
metabolites of glycolysis, graphed from left to right, from top to bottom in their order of appearance in the Embden-Meyerhoff pathway. 
Grouped columns in the left indicate TAp63α-expressing (doxycyline supplemented cells – Dox +), while columns in the right refer to 
non-induced controls (Dox -). Isotopomers are indicated as M+0 (only light unlabeled 13C atoms), M+6 (for hexoses deriving all six carbon 
atoms from heavy glucose) and M+3 (heavy trioses). Kinetics assays have been performed by harvesting cells at 1, 6, 12 and 24h, from 
medium replacement (which in turn was performed at 24h from doxycyline supplementation). * and # indicate statistical significance for 
inter-group (Dox + vs Dox -) or intra-group variations (time-course analyses). The number of * and # is related to p-values < 0.05; 0.01 or 
0.001, respectively.
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to increase of anabolic branch pathways derived from 
glycolysis (Fig. 1A). Therefore we next investigated 
whether the accumulation of glycolytic intermediates 
was associated to an increase in refueling of pentose 
phosphate pathway (PPP). Induced-expression of TAp63α 
indeed was also accompanied by the accumulation of 
labeled PPP intermediates, both of the oxidative phase 
(glucose 6-phosphate, 6-phosphogluconate) and non-
oxidative phase (sedoheptulose 7-phosphate and ribose 
phosphate – and isobaric non-oxidative PPP compounds) 
(Fig. 2A-D), indirectly suggestive of a PPP-mediated 
increase in NADPH/NADP+ ratios. On the other side, the 
TAp63α-dependent increase of PPP was compensated by a 
downregulation of the potentially pro-oxidant hexosamine 
pathway, as gleaned through double metabolic labeling 
(Suppl. Fig. 2A,B). 
Despite higher accumulation of labeled ribose 
(Fig. 2D), slower incorporation of heavy ribose moiety 
was observed in purine nucleotides in 13C-glucose 
experiments (Suppl. Fig. 3A), suggestive of a likely 
enzymatic blockade downstream to ribose. Further 
steps of nucleotide de novo synthesis were deregulated 
in response to the expression of TAp63α, as confirmed 
through 13C15N-glutamine labeling experiments (Suppl. 
Fig.3.B). Impaired nucleotide biosynthesis was consistent 
with the previously reported[27] and hereby confirmed 
TAp63α–depdendent cell cycle blockade at the G1 phase 
and decrease in S phase (Suppl. Fig. 1B).
Effect of TAp63α on serine and GSH homeostasis
Serine levels are relevant in cancer cells [for 
review Amelio et al.[31], since serine influences pyruvate 
kinase M2 (PKM2) activity, and thus the glycolytic 
rate of the cell and de novo biosynthesis of serine itself 
[32]. The efficiency of this pathway is regulated under 
serine starvation in a p53/p21-dependent[13] and p73-
dependent fashion [24]. Serine anabolism also fuels the 
biosynthesis of other key aminoacids, such as glycine 
and cysteine, through transamination reactions that 
contribute to the cellular anaplerotic flux of glutamine 
Figure 2: Effect on Pentose Phosphate Pathway. Isotopomer distribution of metabolites of the Pentose Phosphate Pathway, graphed 
from A to D in their order of appearance (oxidative and non-oxidative arms). Grouped columns in the left indicate TAp63α-expressing 
(doxycyline supplemented cells – Dox +), while columns in the right refer to non-induced controls (Dox -). Isotopomers are indicated as 
M+0 (light, no heavy 13C atoms incorporated), M+6 or M+5 (for hexoses and pentoses deriving all their carbon atoms from heavy glucose). 
Kinetics assays have been performed by harvesting cells at 1, 6, 12 and 24h from medium replacement (which in turn was performed at 
24h from doxycyline supplementation). * and # indicate statistical significance for inter-group (Dox + vs Dox -) or intra-group variations 
(time-course analyses). The number of * and # is related to p-values < 0.05; 0.01 or 0.001, respectively. 
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to glutamate. Cysteine, glycine and glutamate can thus 
promote GSH anabolism, or fuel tricarboxylic acid (TCA) 
cycle via glutamate-derived α-ketoglutarate[33,34]. From 
a metabolomics standpoint, serine light isotopomers 
(either uptaken from the supernatant or deriving from 
proteolysis) progressively decreased both in doxycycline-
supplemented and untreated controls (Suppl. Fig. 4). 
Labeling experimental approaches either using 13C-glucose 
or 13C15N-glutamine revealed a TAp63α-dependent 
accumulation of heavy labeled serine (Suppl Fig. 5). This 
can either derive from a reduced consumption of serine in 
induced cells, or from a TAp63α-dependent stimulation 
of serine biosynthesis similarly to the family members 
p53[32] and TAp73[24]. Conversely, conversion of serine 
in glycine appeared reduced, consistently with a likely 
minor serine consumption in induced cells. Indeed, serine-
derived glycine biosynthesis was slower in doxycycline-
treated cells compared to controls both in 13C-glucose and 
13C15N-glutamine labeling experiments (Suppl. Fig. 5B-E). 
Analogously, heavy labeled cystathionine (an intermediate 
of cysteine biosynthesis from serine and homocysteine) 
was lower in TAp63α overexpressing cells (Suppl. Fig. 
5C-F). 
Recently, p73-dependent serine biosynthesis has 
been coupled to GSH homeostasis in cancer[22,24]. Owing 
to relative abundances (Suppl. Fig. 4), GSH incorporation 
of heavy isotopomers from glycine and cysteine was 
expected to be negligible. On the other hand, isotopomer 
distribution of GSH in 13C-glucose experiments was 
consistent with the progressive incorporation of heavy 
labeled glutamate (Fig. 3A, Suppl. Fig. 4). Overall, minor 
albeit significant heavy isotopomer incorporation in GSH 
was observed in induced cells during time-course analyses 
(Fig. 3A – from glucose; D - from glutamine), despite total 
GSH being comparable to non-induced controls (Fig. 
3B,E). On the other hand, glutamate incorporation from 
labeled glutamine in GSH was higher in induced cells in 
comparison to controls only before reaching the steady 
state (<6h from medium replacement - Fig. 3F). TAp63α-
dependent glutamate utilization in GSH biosynthesis 
Figure 3: Effect on GSH homeostasis. (A-F) Heavy and total isotopomers of reduced and oxidized glutathione (GSH and GSSG, 
respectively), as representative metabolites for oxidative stress accumulation. In A, heavy isotopomers are reported on the basis of the 
presence of heavy glucose derived 13C atoms, such as M+2, M+3 and M+4, M+5 and M+7 (sum of the previous). While glycine and 
cysteine labeling is expected to be low in the light of their relative abundance in comparison to the light M+0 isotopomers (Suppl. Fig. 4), 
heavy C atoms might be incorporated from glutamate derived via transamination of labeled ketoglutarate from acetyl-CoA produced via 
glycolytic consumption of labeled glucose (Suppl. Fig. 6A) (J-L). Isotopomer distribution of glutathione in glutamine labeling experiments. 
Grouped columns in the left indicate TAp63α-expressing (doxycyline supplemented cells – Dox +), while columns in the right refer to non-
induced controls (Dox -). Isotopomers are distributed as follows: M+5+1 (fully labeled glutamate in both carbon and nitrogen atoms), M+5 
(glutamate labeled only in carbon atoms). M+2 and M+3 (fast equilibrium with ketoglutarate; M+4 and 4+1 isotopomers were not detected). 
Kinetics assays have been performed by harvesting cells at 1, 6, 12 and 24h from medium replacement (which in turn was performed at 
24h from doxycyline supplementation). From left to right, the graphs represent only heavy isotopomers (J), all isotopomers (K), and only 
heavy isotopomers in Dox + against Dox – cells at 1h after medium replacement (L). In L, differential results were statistically significant 
(p < 0.01 Student’s t-test). Kinetics assays have been performed by harvesting cells at 1, 6, 12 and 24h from medium replacement (which 
in turn was performed at 24h from doxycyline supplementation). * and # indicate statistical significance for inter-group (Dox + vs Dox -) 
or intra-group variations (time-course analyses). The number of * and # is related to p-values < 0.05; 0.01 or 0.001, respectively.
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Figure 4: Effect on Krebs cycle (heavy labeled isotopomers only). (A) Distribution of heavy isotopomers of metabolites 
of the Krebs cycle from 13C-glucose labeling experiments, graphed from left to right, from top to bottom in their order of appearance 
in the oxidative reactions of the TCA cycle pathway. Isotopomers are indicated as M+5 (incorporating five 13C atoms) or M+10 (for 
nucleotides deriving one or two ribose moieties from heavy glucose), M+2, M+3, M+4, M+5, M+6 (progressively heavy labeled Krebs 
cycle intermediates from glucose-derived acetyl-CoA). (B). Distribution of heavy isotopomers of metabolites of the Krebs cycle from 
13C15N-glutamine labeling experiments. Isotopomers are distributed as follows: M+4 (incorporating four 13C atoms, i.e. fully labeled from 
glutamine-derived ketoglutarate), M+2 and +1 (subsequent oxidative cycles of the TCA supplied by other unlabeled carbon sources than 
labeled glutamine). M+3 isotopomers of succinate, fumarate and malate would derive from reductive carboxylation of ketoglutarate. 
Grouped columns in the left indicate TAp63α-expressing (doxycyline supplemented cells – Dox +), while columns in the right refer to non-
induced controls (Dox -). Kinetics assays have been performed by harvesting cells at 1, 6, 12 and 24h from medium replacement (which in 
turn was performed at 24h from doxycyline supplementation). * and # indicate statistical significance for inter-group (Dox + vs Dox -) or 
intra-group variations (time-course analyses). The number of * and # is related to p-values < 0.05; 0.01 or 0.001, respectively.
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suggests that glutamate might represent a limiting factor 
driving TAp63α-mediated responses to oxidative stress, 
accumulating in the form of GSSG in non-induced cells 
(Fig. 3C). Together with the up-regulation of the NADPH-
generating PPP, these results are suggestive of a likely 
antioxidant effect mediated by TAp63α. 
TAp63α expression decreases the fueling of 
glucose and glutamine in Krebs cycle
Defects of Krebs cycle enzymes and a reduced rate 
of oxidative phosphorylation are tied to cancer, as they 
can contribute to tumor progression or suppression [35]. 
In glucose labeling experiments, heavy labeling of Krebs 
cycle precursors and intermediates (including acetyl-CoA, 
citrate, α-ketoglutarate, succinate, fumarate and malate) 
was reduced upon TAp63α overexpression (Fig. 4A). 
However, the total levels of Krebs cycle intermediates 
did show statistically significant changes only in early 
time points (Suppl. Fig. 4A). In late time points, light 
isotopomers compensated for the lower amounts of 
heavy labeled counterparts in TAp63α expressing 
cells (Suppl. Fig. 6A). This was with the exception of 
succinate. Indeed, succinate level was highly altered in 
the oxidative arm of the Krebs cycle in response to the 
induced expression of TAp63α (Fig. 4A). In the light 
of these results, we next hypothesized that some other 
carbon sources, such as glutamine, could progressively 
fuel Krebs cycle upon induction of TAp63α. Indeed, p63 
is also known to promote the expression of glutaminase 2 
[36], the metabolic enzyme responsible for the conversion 
of glutamine in glutamate, and also therefore partially 
responsible of the control of anaplerotic flux. However, 
in glutamine labeling experiments, no statistically 
significant alterations were observed in intracellular total 
and heavy glutamine levels (Suppl. Fig. 7A,B), as well as 
in glutamine conversion to glutamate (heavy isotopomers 
- Supp Fig. 7C-D). On the other hand, utilization of 
labeled-glutamate to produce α-ketoglutarate was more 
sustained in control cells than in TAp63α expressing cells 
(Suppl. Fig. 7E,F). Also glutamine-labeling experiments 
showed a substantial decrease of succinate levels in TAp63 
expressing cells (Fig. 4B, Suppl. Fig. 6B), which might 
indicate that less glutamine is committed to the TCA cycle, 
consistently with lower labeling of TCA intermediates 
downstream to alpha-ketoglutarate (Fig. 4B). Alternative 
explanations imply that decreased levels of succinate might 
either result from a blockade of the upstream oxoglutarate 
dehydrogenase or succinyl-CoA ligase, or rather suggest 
an alternative fate for succinate. Downstream to succinate, 
reduction in fumarate and malate levels showed minor, 
albeit statistically significant, deviations from control 
levels (Fig. 4B). Isotopomer distribution in 13C-glucose 
experiments suggests that oxidative Krebs cycle 
intermediates down-stream to ketoglutarate might be 
fluxed from other precursors in addition to glutamate, or 
rather be produced as a result of reductive carboxylation. 
Indeed, glutamate-derived ketoglutarate can either enter 
in to oxidative Krebs cycle or rather serve as a substrate 
for reductive carboxylation reactions [37], thus enabling 
the cells to replenish acetyl-CoA reservoirs for anabolic 
purposes, such as fatty acid biosynthesis (Suppl. Fig. 8). 
Although TAp63 overexpressing cells showed reduction 
of glutamine-derived alpha-ketoglutarate, they presented 
similar levels of reductive carboxylation-derived 
isotopomers (+5 citrate and aconitate, +3 malate and 
fumarate, +2 acetyl-CoA). However, it is worth noting that 
these isotopomers can accumulate without net reductive 
carboxylation flux, even in hypoxic cells or cells with 
IDH mutations [38,39]. While total ATP levels did not 
change between doxycyline-supplemented and untreated 
cells, induced expression of TAp63α corresponded to a 
faster accumulation of the reduced form of the coenzyme 
nicotinammide adenine dinucleotide (NADH) (Suppl. Fig. 
4A). NADH is a key marker of energy metabolism, and 
its accumulation is an indirect indicator of the glycolsys/
mitochondrial metabolism [40], as it either accompanies 
malignant transformation or the up-regulation of PPP and 
serine biosynthesis at the expenses of lactic fermentation 
[41]. 
TAp63α might influence fatty acid synthesis
Recent literature suggests a role for p63 in the 
promotion of fatty acid synthesis and depression of beta-
oxidation by transcriptionally activating Sirt1, AMPKα2, 
and LKB1 [26]. By monitoring labeled acetyl-CoA, 
either derived from glucose or glutamine, we investigated 
fatty acid biosynthesis rates [37], hereby determined by 
analyzing the isotopomeric distribution of palmitate. As 
a result, glutamine-derived acetyl-CoA was more rapidly 
fluxed toward palmitate anabolism in TAp63α expressing 
cells in comparison to non-induced controls (Suppl. Fig. 
9A,B). However, it is worth noting that labeled palmitate 
was but a minor percentage of the total palmitate (Supp. 
Fig 9 C,D), and that fatty acid labeling from glutamine in 
hypoxia can be explained by spreading of label without net 
reductive IDH flux [38].
TAp63-dependent regulation of metabolism 
represents a prognostic factor in cancer
We next evaluated the clinical relevance in human 
cancers of TAp63-dependent regulation of cellular 
metabolism. By using a bioinformatic approach we 
implemented a series of coexpression analysis with patient 
survival estimation in human breast cancer datasets. 
Assessment of the impact on prognosis of correlation 
between p63 and metabolic enzymes would suggest a 
clinical relevance of this molecular axis in human cancers. 
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First we used a big dataset from METABRIC (Molecular 
Taxonomy of Breast Cancer International Consortium). 
METABRIC dataset is a collection of over 2,000 clinically 
annotated primary fresh-frozen breast cancer specimens 
subjected to copy number and gene expression profiling 
[42]. The survival annotation of the patients was used to 
select two cohorts of patients. Top 10% patients with the 
best-observed survival parameters were selected as “good 
prognosis” subset (~200 samples) while low 10% with the 
worst survival records were selected as “poor prognosis” 
subset (~200 samples) (Fig. 5A). Next, we computed 
Pearson correlation coefficient between TP63 expression 
profile and profiles of genes from the PPP for each subset 
of patients (“good” and “poor” prognosis). Our analysis 
demonstrated that in patients with non-aggressive cancer 
we observe significant correlation of mRNA expression 
between p63 and most genes from the pathways while in 
patients with aggressive cancer this link is absent (Fig. 
5B). Interestingly, the only exception was for glucose-6 
phosphate dehydrogenase (G6PD), whose correlation 
with p63 was mainly identified in bad prognosis subgroup 
(Fig. 5B). G6PD is the rate-liming step of PPP, converting 
glucose-6-phosphate to 6-phosphate-gluconolactone. The 
PPP is a major glucose metabolic pathway required for 
cellular demands of anabolism and antioxidant defense. 
PPP indeed has emerged among the major metabolic 
pathways involved in malignancies. Hence we decided 
to investigate deeper whether the TAp63-dependent 
regulation of this pathways showed a relevant function for 
cancer prognosis. We selected an additional human breast 
cancer dataset and we split the samples in two cohorts. The 
first cohort included all the samples to maximize positive 
correlation between p63 and the metabolic enzyme, while 
in the second cohort all the other samples were included. 
This clusterization divided the dataset in two biological 
groups: “Correlation” and “No Correlation”. Then, we 
computed survival estimation for the two cohorts, thus 
estimating the prognostic ability of the gene correlation. 
This algorithm was applied to the clinical datasets 
to assess p63 correlation with the major enzymes of 
PPP (Glucose-6-phosphate dehydrogenase, G6PD and 
6-phosphogluconate dehydrogenase, PGD). As shown 
Figure 5: Bioinformatic validation of p63 in cancer metabolism. (A) Survival estimation curves of top 10% (good prognosis) 
and low 10% (bad prognosis) survival outcome from Metabric dataset. Each cohort includes approximately 200 samples. (B) Table showing 
correlation factors between p63 and metabolic enzymes of interest in the two cohorts “good prognosis” and “bad prognosis”. In dark green 
positive correlation, in red negative correlation. (C-D) Positive p63/G6PD and p63/PDG correlations (“Correlation” subgroups, in green) 
represent a negative prognostic factor for survival of breast cancer patients. Breast cancer datasets (GSE3494) was split in two cohorts ‘p63/
metabolic enzyme Interaction’ and ‘p63/metabolic enzyme NO Interaction’ on the basis of existence or not of their correlation. Survival 
estimation was compute to show prediction of survival outcome for the two cohorts.
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in Figure 5C,D, the analysis revealed that the existence 
of p63 correlation with G6PD, PGD, predicted negative 
prognosis in breast cancer. These analyses revealed that 
cancer cell might benefit from the existence of p63-
dependent regulation of this metabolic pathway. Although 
bioinformatics analyses did not discriminate among p63 
isoforms, the importance of PPP and serine biosynthesis 
for the maintenance of redox balance, was also confirmed 
by the hereby observed increased GSH level in TAp63 
expressing cells, suggested that TAp63 might support cell 
redox homeostasis by promoting their cellular antioxidant 
defense. 
In summary, the present study indicates that TAp63α 
induces a wide series of metabolic consequences (Suppl. 
Fig. 10). Induced expression of TAp63α in SaOs-2 cells 
boosted cell glycolysis and reduced glucose derivative 
channeling to the Krebs cycle. By promoting the 
accumulation of early glycolytic intermediates, TAp63α 
favored the glycolytic branching towards the PPP, which 
was uncoupled from nucleotide biosynthesis albeit 
prevented GSSG accumulation. Results also suggested 
that TAp63α might either promote a lower consumption 
or a faster rate of serine biosynthesis, which however did 
not correspond to increased leves of labeled glycine and 
cysteine. TAp63α depressed glutamine-derived glutamate 
utilization to fuel catabolic reactions in the TCA cycle. 
However, from the present results we could observe only 
minor Tap63α-dependent increases of glutamine-derived 
labeling in palmitate, though it is unclear whether this 
could be tied to increased rates of reductive carboxylation 
and de novo synthesis of fatty acids. These findings 
highlight the importance of TAp63 for the maintenance of 
antioxidant defense and contribute to elucidate the role of 
TAp63 in cellular metabolism. 
METHODS
Cell culture and reagents
Human osteosarcoma SAOS-2 with doxycycline-
inducible expression of HA-TAp63α were cultured in 
Dulbecco’s modified Eagle’s medium (Gibco, Invitrogen), 
supplemented with 10% fetal bovine serum (FBS), 100 
µg/ml penicillin and 100 µg/ml streptomycin (all Gibco, 
Invitrogen) and cultured at 37 C° with 5% CO2. To induce 
TAp63α expression, Saos-2- TAp63α cells were grown in 
the presence of doxycyclin (2.5 μg/ml) for 12, 24 and 48 
hours as previously reported [27].
Metabolomics experiments
Saos-2 cells (0.5x106) were seeded in triplicate wells 
of 6-well plates in high glucose DMEM supplemented 
with supplemented with 10% fetal bovine serum (FBS), 
100µg/ml penicillin and100 µg/ml streptomycin (Gibco, 
Invitrogen) and 2mM L-glutamine. Duplicate plates 
were seeded for cell counts. After 24 h from doxycyline 
supplementation to the medium (2.5μg/ml), cells were 
washed with PBS and received heavy 13C-glucose or 
13C15N-glutamine-substituted media (Cambridge Isotopes). 
Extraction of metabolites was performed at 1, 
6, 12 and 24h upon supplementation of heavy labeled 
media (0h = 24h from TAp63α induction via doxycycline 
supplementation). Cells were washed with PBS and 
metabolites extracted using methanol/acetonitrile/dH2O 
(5:3:2) (1–2x106 cells per ml). Samples were vortexed 
for 30minutes at 4°C and thus centrifuged at 16000g 
for 15min at 4°C. Supernatants were collected for 
subsequent analyses. MS analyses were performed in 
polarity switch mode on an Orbitrap Exactive (Thermo 
Scientific) in line with an Accela autosampler and an 
Accela 600 pump (Thermo Scientific). Column hardware 
consisted of a Sequant ZIC-pHILIC column (2.1x150mm, 
5µm) coupled to a Sequant ZIC-pHILIC guard column 
(2.1x20mm, 5 µm) (Merck). Flow rate was 100 ml min-1, 
buffers consisted of acetonitrile (ACN) for A, and 20mM 
(NH4)2CO3, 0.1% NH4OH in ddH2O for B.
Gradient ran from 80% to 40% ACN in 20min, 
followed by a wash at 20% ACN and re-equilibration at 
80% ACN. Metabolites were identified and quantified 
using LCquan software (Thermo Scientific). Metabolites 
were positively identified on the basis of exact mass 
within 5 p.p.m., further validated by concordance with 
standard retention times and plotted as the peak area for 
each metabolite. Isotopomer distributions were determined 
on the basis of the expected reactions involving the 
investigated metabolite and by looking the actual 
isotopomeric distribution of mass spectra chromatograms. 
Results were graphed with Graphpad Prism 5.01 
(Graphpad Software Inc) as means + SD. Statistical 
analyses were performed with the same software, as 
a result of paired t-test or two-way ANOVA among the 
results obtained from doxycycline supplemented (dox+) 
and non-supplemented (dox-) cells at the steady state or 
in a time-dependent fashion (independent variables being 
doxycycline supplementation and time-course assays). 
Immunoblot analysis, antibodies and cell cycle 
analysis
Immunoblot analysis was performed using whole 
cell extracts obtained by lysing cell pellets with Triton 
Buffer (, supplemented with protease and phosphatase 
inhibitors (Sigma). Proteins were separated by SDS-
PAGE (either 8 or 10%, depending on the MW range of 
the assayed protein), transferred onto PVDF membranes 
and blocked with TBS buffered saline and 0,1%Tween-20, 
containing 5% non-fat dry milk for one hour at room 
temperature (RT). The incubation with primary antibodies 
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was performed for two hours at RT. Antibodies used 
included: anti-HA (mouse, 1:1000; Clone 16B12 N. 
MMS101P - Covent), anti-beta actin (mouse, 1:2000; 
Clone C4 (Millipore) Lot n. 2065987), and anti-p21 (goat, 
1:1000; p21 (c-19) sc-397-G - Santa Cruz). Incubation 
with the appropriate secondary antibody either included 
LICOR secondary Ab: anti-mouse IgG (donkey, 1:20000; 
green (800CW) - LT 926-32212 Lot no. C10707-01 
(Odyssey)), anti-mouse IgG (donkey, 1:20000; red (IRDye 
680) - LT 926-68022 Lot no. C10921-02 (Odyssey)), anti-
rabbit IgG (donkey, 1:20000; green (800CW) - LT 926-
32213 Lot no. C11020-03 (Odyssey)). Detection was 
performed with a LICOR scanning apparatus (Odyssey). 
Cell cycle Analysis
Quantification of sub-G1 population and cell cycle 
phase was performed by FACS analysis of propidium 
iodide-staining nuclei, carried out in a FACScan flow 
cytometer (Becton Dickinson, Heidelberg, Germany) 
using the CELLQuest software system. For sub-G1 
analysis, cells were grown and detached from plates via 
trypsinization, then fixed and stained with propidium 
iodide (PI, 50mg/ml) for 30 min. For cell-cycle analysis 
BrdU (Invitrogen) was added to live cells for 100min and 
detected as described previously [27]. Flow cytometry was 
performed on a FACSCalibur cytometer. For PI exclusion, 
PI was added to cell culture medium (1 mg/ml) for 5min. 
Non-adherent and adherent cells were collected and 
analysed by Flow cytometry on a FACSCalibur cytometer.
Bioinformatics analyses
For correlation analysis between p63 and metabolic 
enzymes in top and low 10% patients from Metabric 
dataset, we computed Pearson correlation coefficient 
between p63 expression profile and profiles of genes 
from the pathway for each subset of patients (“good” and 
“poor” prognosis). The p-values were computed using 
Monte-Carlo simulation procedure. The null hypothesis 
that was tested for each genes pair assumed correlation 
of expression between p63 and a gene from the pathways 
(next referred to as a gene P) in a cohort of selected 
samples to be equal to the correlation in the whole set 
of samples. To estimate the p-value, a random cohort of 
samples has been sampled 1000 times and correlation 
between p63 and a gene P has been computed. Therefore, 
we deduced a distribution (of size 1000) of correlation 
between p63 and a gene P in a randomly selected cohort of 
~200 samples. The values in the distribution are compared 
to the value of correlation in the selected cohort of patients 
and p-value is computed. For example, for pair p63 and 
SUCLA2 the estimated p-value is < 0.001 which indicates 
that no one time in 1000 simulations the correlation 
between p63 and SUCLA2 in the randomly selected cohort 
of patients has been higher than 0.25 which is correlation 
between p63 and SUCLA2 in “good prognosis” cohort of 
patients.
For the survival estimation analysis in p63/G6PD 
or p63/PDG positive and negative groups we computed 
correlation between of p63 and enzymes expression 
profiles in cohort 1 as well as compute the changes in 
correlation if one sample from the cohort would be 
removed. The sample with maximal effect on correlation 
(maximal increase in positive correlation) is moved from 
cohort 1 to cohort 2. The same procedure is repeated 
next until there would be no one sample which could be 
removed from cohort 1 so to increase positive correlation 
between p63 and the metabolic enzymes. The separation 
of patients into “cohort 1” and “cohort 2” along with 
survival information is next used to find any statistical 
differences in survival outcome. The R statistical package 
is used to perform survival analyses and to draw KMplots.
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